Org 28611

Org 28611
Systematic (IUPAC) name
	[1-(cyclohexylmethyl)-7-methoxyindol-3-yl]-[(3S)-3,4-dimethylpiperazin-1-yl]methanone
Clinical data
Legal status	CA: Schedule II;
Identifiers
CAS Number	639068-99-8
PubChem	CID: 10091392
ChemSpider	8266929
ChEMBL	CHEMBL1209709
Chemical data
Formula	C23H33N3O2
Molecular mass	383.526 g/mol
	SMILES COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4 ;
	InChI InChI=1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1 ; Key:ONXJNAIZJKLJGA-KRWDZBQOSA-N ;
(what is this?) (verify)

Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB₁ and CB₂ receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic,^[1] and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.^[2]^[3]

References

↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.